Cadrenal Therapeutics, Inc. Stock-Based Compensation
Cadrenal Therapeutics, Inc. (CVKD) reported Stock-Based Compensation of $924.47 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $672.10K, a 13.41% increase year-over-year.
- Cadrenal Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $252.36K, a 54.01% decline year-over-year.
- Cadrenal Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $325.10K, a 57.40% decline year-over-year.
- Cadrenal Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $473.38K, a 57.81% increase year-over-year.
- Cadrenal Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.94M, a 36.70% increase from fiscal 2024.
- Cadrenal Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.42M, a 99.76% increase from fiscal 2023.
- Cadrenal Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $710.38K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 8 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 11 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $672.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $924.47K 10-Q · filed 2026-08-13 | $1.25M derived: sum of 3 quarters · filed 2026-08-13 | $1.72M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $252.36K 10-Q · filed 2026-05-07 | $577.47K derived: sum of 2 quarters · filed 2026-05-07 | $1.05M derived: sum of 3 quarters · filed 2026-05-07 | $1.64M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $325.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $798.49K derived: sum of 2 quarters · filed 2026-03-31 | $1.39M derived: sum of 3 quarters · filed 2026-08-13 | $1.94M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $473.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.07M derived: sum of 2 quarters · filed 2026-08-13 | $1.61M 10-Q · filed 2025-11-10 | $2.38M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $592.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.14M 10-Q · filed 2026-08-13 | $1.90M derived: sum of 3 quarters · filed 2026-08-13 | $2.20M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $548.76K 10-Q · filed 2026-05-07 | $1.31M derived: sum of 2 quarters · filed 2026-05-07 | $1.61M derived: sum of 3 quarters · filed 2026-05-07 | $1.81M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $763.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.06M derived: sum of 2 quarters · filed 2026-03-31 | $1.26M derived: sum of 3 quarters · filed 2026-03-31 | $1.42M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $299.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $493.10K derived: sum of 2 quarters · filed 2025-11-10 | $655.83K 10-Q · filed 2025-11-10 | $758.95K derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $193.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $355.85K 10-Q · filed 2025-08-11 | $458.97K derived: sum of 3 quarters · filed 2025-08-11 | $612.04K derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $162.73K 10-Q · filed 2025-05-08 | $265.85K derived: sum of 2 quarters · filed 2025-05-08 | $418.92K derived: sum of 3 quarters · filed 2025-05-08 | $586.72K derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $103.11K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $256.19K derived: sum of 2 quarters · filed 2025-03-13 | $423.99K derived: sum of 3 quarters · filed 2025-03-13 | $710.38K 10-K · filed 2025-03-13 | ||
| 2023-09-30 | $153.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $320.87K derived: sum of 2 quarters · filed 2024-11-07 | $607.27K 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $167.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $454.19K 10-Q · filed 2024-08-07 | ||||
| 2023-03-31 | $286.40K 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $928.05K 10-K · filed 2024-03-11 | |||||
| 2022-09-30 | $478.68K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |